SINGAPORE (The Straits Times/ANN): The Health Sciences Authority (HSA) has approved 11 applications for private hospitals and clinics to import China's Sinopharm vaccine under the special access route (SAR).
This means the risks of using such vaccines are "fully borne by the doctor and vaccine recipient", a HSA spokesman said.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!